Kodiak Sciences stock: Q3 earnings are expected November 12, 2026

Kodiak Sciences stock (ISIN US50015M1099) has a scheduled reporting date on November 12, 2026, when the biotechnology company is expected to publish third-quarter results. MarketBeat says the announcement is expected after the market close, with a conference call scheduled for 4:00 p.m. ET. Kodiak Sciences was trading at EUR 76.49 at Lang & Schwarz on October 22, 2026 at 10:44 p.m. CEST.

Losses shape the next report

The upcoming report follows a second-quarter net loss of USD 65.64 million, or USD 1.05 per diluted share, for the period ended June 30, 2026. RTTNews reported that the loss widened from USD 54.3 million in the prior-year quarter, while cash and cash equivalents stood at USD 125.9 million at June 30, 2026.

That financial profile is consistent with Kodiak's clinical-stage status. The company is developing retinal medicines rather than selling an approved commercial product, and its investor-relations materials describe three late-stage clinical programs, including Zenkuda and KSI-501. Kodiak Sciences identifies Zenkuda as its lead investigational medicine for retinal vascular diseases.

Stock remains below its yearly high

The Nasdaq-listed stock was trading at USD 85.78 on October 22, 2026 at 4:00 p.m. EDT. Its 52-week range was USD 15.83 to USD 104.00, placing the latest U.S. quotation USD 18.22 below the high, or 17.52 percent below it. Market capitalization stood at USD 5.4 billion on the same date, while volume reached 593,403 shares.

Valuation meets a fixed date

The trailing price-to-earnings ratio was negative 20.47 on October 22, 2026, reflecting the company's reported loss. The next scheduled date is November 12, 2026, after market close, although MarketBeat describes the date as an estimate based on prior reporting schedules. The main investor question is whether the third-quarter release changes the cash-runway picture established in June.

What the November date brings

The November release should provide the next periodized update on operating expenses, cash consumption and clinical progress. Kodiak's latest investor materials say the DAYBREAK program has completed enrollment and that its lead programs remain in late-stage development, keeping clinical execution central to the company's valuation.

Stock price and reporting date

The euro quotation stood at EUR 76.49 at Lang & Schwarz on October 22, 2026 at 10:44 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Kodiak Sciences stock.

Market context: Market report S&P 500.

More news and analyses on Kodiak Sciences stock